Pure Global AI
NCT06023199Recruiting

Assessing Physical Function in Sickle Cell Patients Taking Voxelotor

Assessing Functional Capacity in Sickle Cell Patients Receiving Voxelotor
Inova Health Care ServicesClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Sickle Cell Disease
Drug/Device/Intervention
Voxelotor
Study type
Observational
Intervention type
drug
Sponsor & location
Primary sponsor
Inova Health Care Services
Location
Falls Church, United States of America
Timeline & enrollment
Phase
N/A
Start date
Oct 23, 2023
End date
Jun 15, 2024
Enrollment
10 participants
Primary outcome

Participant's Physical Performance Using 6 Minutes Walk Test (6MWT) Pre and Post Treatment with Voxelotor.

Summary

Voxelotor is a novel hemoglobin polymerization inhibitor which has been demonstrated to
 reduce hemolysis and improve hemoglobin levels. There have been numerous studies examining
 the clinical impact of voxelotor in sickle cell disease (SCD) patients, but there are few
 published reports on the effects of treatment on physical function in patients with SCD. The
 hypothesis to be tested is that anemic SCD patients will have improvements in performance
 after 6 months of voxelotor treatment.

ICD-10 classifications
Sickle-cell disordersOther sickle-cell disordersSickle-cell traitSickle-cell anaemia with crisisSickle-cell anaemia without crisis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06023199
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06023199 through Pure Global AI's free database. This phase not specified trial is sponsored by Inova Health Care Services and is currently Recruiting. The study focuses on Sickle Cell Disease. Target enrollment is 10 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.